Carboplatin plus nab-Paclitaxel versus docetaxel for elderly squamous non-small cell lung cancer (CAPITAL study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2022 Results (n=190) assessing safety analysis for patients less than and greater than equal to 75 years old from each treatment group, post-hoc analysis of the impact of second-line immune checkpoint inhibitors (ICI) on survival, and intra-cycle nab-paclitaxel skip status, presented at the 47th European Society for Medical Oncology Congress.
21 Sep 2021 Results assessing the extent to which dose and schedule modifications of carboplatin and nab-paclitaxel were necessary in elderly patients with squamous non-small cell lung cancer, presented at the 46th European Society for Medical Oncology Congress.
08 Jun 2021 Primary endpoint (Overall survival) has been met, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com